• Medical Information Documents

  • On Demand Medical Videos

    • Congress Data

      DTG/3TC: Real-World Evidence

      DTG/3TC: Real-World Evidence

      An Update from CROI 2020
      Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

      DTG/3TC: Real-World Evidence

      An Update from CROI 2020
      Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
      DTG: Metabolic Data Update

      DTG: Metabolic Data Update

      Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

      DTG: Metabolic Data Update

      Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
      Very Low Levels of Viral Replication for DTG/3TC Versus 3DR: The TANGO Study

      Very Low Levels of Viral Replication for DTG/3TC Versus 3DR: The TANGO Study

      Mark Underwood, Clinical Virologist and Development Investigator

      Very Low Levels of Viral Replication for DTG/3TC Versus 3DR: The TANGO Study

      Mark Underwood, Clinical Virologist and Development Investigator
      TANGO Study: Metabolic Substudy

      TANGO Study: Metabolic Substudy

      Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

      TANGO Study: Metabolic Substudy

      Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
      DTG+3TC: GEMINI 144-Week Data

      DTG+3TC: GEMINI 144-Week Data

      An Update from HIV GLASGOW 2020
      Nneka Nwokolo, Senior Global Medical Director

      DTG+3TC: GEMINI 144-Week Data

      An Update from HIV GLASGOW 2020
      Nneka Nwokolo, Senior Global Medical Director
      DTG+3TC: TANGO 96-Week Data

      DTG+3TC: TANGO 96-Week Data

      An Update from HIV GLASGOW 2020
      Jose Gatell, Senior Global Medical Director

      DTG+3TC: TANGO 96-Week Data

      An Update from HIV GLASGOW 2020
      Jose Gatell, Senior Global Medical Director
      DTG/3TC: Barrier to Resistance

      DTG/3TC: Barrier to Resistance

      Jan van Lunzen, Head of Translational Medical Research

      DTG/3TC: Barrier to Resistance

      Jan van Lunzen, Head of Translational Medical Research
      Post-CROI 2021 Webinar

      Post-CROI 2021 Webinar

      Andrew Zolopa, MD, VP, Head, North America Medical Affairs

      Post-CROI 2021 Webinar

      Andrew Zolopa, MD, VP, Head, North America Medical Affairs
      GEMINI 144 Week: Efficacy and Safety

      GEMINI 144 Week: Efficacy and Safety

      Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

      GEMINI 144 Week: Efficacy and Safety

      Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
      TANGO 96 Week: Efficacy and Safety

      TANGO 96 Week: Efficacy and Safety

      Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

      TANGO 96 Week: Efficacy and Safety

      Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
      GEMINI 48 Week: Adherence Analysis

      GEMINI 48 Week: Adherence Analysis

      Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

      GEMINI 48 Week: Adherence Analysis

      Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
      STAT 24 Week: Feasibility, Efficacy and Safety

      STAT 24 Week: Feasibility, Efficacy and Safety

      Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

      STAT 24 Week: Feasibility, Efficacy and Safety

      Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
    • Clinical Trials Data

      The Use of Tivicay plus Epivir for Treatment-Naïve Adults with HIV-1

      The Use of Tivicay plus Epivir for Treatment-Naïve Adults with HIV-1

      GEMINI-1 and GEMINI-2 Studies
      Michael Aboud, VP, Global Medical Lead, Dolutegravir

      The Use of Tivicay plus Epivir for Treatment-Naïve Adults with HIV-1

      GEMINI-1 and GEMINI-2 Studies
      Michael Aboud, VP, Global Medical Lead, Dolutegravir
      Very Low Levels of Viral Replication for DTG/3TC Versus 3DR: The TANGO Study

      Very Low Levels of Viral Replication for DTG/3TC Versus 3DR: The TANGO Study

      Mark Underwood, Clinical Virologist and Development Investigator

      Very Low Levels of Viral Replication for DTG/3TC Versus 3DR: The TANGO Study

      Mark Underwood, Clinical Virologist and Development Investigator
      TANGO Study: Metabolic Substudy

      TANGO Study: Metabolic Substudy

      Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

      TANGO Study: Metabolic Substudy

      Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
      STAT Study: The Feasibility, Efficacy and Safety of Dovato in a Test-and-Treat Setting

      STAT Study: The Feasibility, Efficacy and Safety of Dovato in a Test-and-Treat Setting

      Andrew Zolopa, MD, VP, Head, North America Medical Affairs

      STAT Study: The Feasibility, Efficacy and Safety of Dovato in a Test-and-Treat Setting

      Andrew Zolopa, MD, VP, Head, North America Medical Affairs
      DTG+3TC: GEMINI 144-Week Data

      DTG+3TC: GEMINI 144-Week Data

      An Update from HIV GLASGOW 2020
      Nneka Nwokolo, Senior Global Medical Director

      DTG+3TC: GEMINI 144-Week Data

      An Update from HIV GLASGOW 2020
      Nneka Nwokolo, Senior Global Medical Director
      DTG+3TC: TANGO 96-Week Data

      DTG+3TC: TANGO 96-Week Data

      An Update from HIV GLASGOW 2020
      Jose Gatell, Senior Global Medical Director

      DTG+3TC: TANGO 96-Week Data

      An Update from HIV GLASGOW 2020
      Jose Gatell, Senior Global Medical Director
      Post-CROI 2021 Webinar

      Post-CROI 2021 Webinar

      Andrew Zolopa, MD, VP, Head, North America Medical Affairs

      Post-CROI 2021 Webinar

      Andrew Zolopa, MD, VP, Head, North America Medical Affairs
      GEMINI 144 Week: Efficacy and Safety

      GEMINI 144 Week: Efficacy and Safety

      Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

      GEMINI 144 Week: Efficacy and Safety

      Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
      TANGO 96 Week: Efficacy and Safety

      TANGO 96 Week: Efficacy and Safety

      Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

      TANGO 96 Week: Efficacy and Safety

      Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
      GEMINI 48 Week: Adherence Analysis

      GEMINI 48 Week: Adherence Analysis

      Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

      GEMINI 48 Week: Adherence Analysis

      Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
      STAT 24 Week: Feasibility, Efficacy and Safety

      STAT 24 Week: Feasibility, Efficacy and Safety

      Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

      STAT 24 Week: Feasibility, Efficacy and Safety

      Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
    • Safety

      Post-CROI 2021 Webinar

      Post-CROI 2021 Webinar

      Andrew Zolopa, MD, VP, Head, North America Medical Affairs

      Post-CROI 2021 Webinar

      Andrew Zolopa, MD, VP, Head, North America Medical Affairs
      DTG: Metabolic Data Update

      DTG: Metabolic Data Update

      Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

      DTG: Metabolic Data Update

      Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
      TANGO Study: Metabolic Substudy

      TANGO Study: Metabolic Substudy

      Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

      TANGO Study: Metabolic Substudy

      Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
      Antiretroviral Therapy and Weight Gain

      Antiretroviral Therapy and Weight Gain

      Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

      Antiretroviral Therapy and Weight Gain

      Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
    • Virology/Resistance

      Very Low Levels of Viral Replication for DTG/3TC Versus 3DR: The TANGO Study

      Very Low Levels of Viral Replication for DTG/3TC Versus 3DR: The TANGO Study

      Mark Underwood, Clinical Virologist and Development Investigator

      Very Low Levels of Viral Replication for DTG/3TC Versus 3DR: The TANGO Study

      Mark Underwood, Clinical Virologist and Development Investigator
      DTG/3TC: Barrier to Resistance

      DTG/3TC: Barrier to Resistance

      Jan van Lunzen, Head of Translational Medical Research

      DTG/3TC: Barrier to Resistance

      Jan van Lunzen, Head of Translational Medical Research
    • Real World Evidence

      Dovato Real World Evidence Video

      Dovato Real World Evidence Video

      Dr. Benjamin Young, Head of Global Medical Directors

      Dovato Real World Evidence Video

      Dr. Benjamin Young, Head of Global Medical Directors
      DTG/3TC: Real-World Evidence

      DTG/3TC: Real-World Evidence

      An Update from CROI 2020
      Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

      DTG/3TC: Real-World Evidence

      An Update from CROI 2020
      Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
    • Treatment Naïve Data (GEMINI 1 & 2 Studies)

      Week 48 Results

      Week 48 Results

      Week 48 Results

      Week 144 Results

      Week 144 Results

      Week 144 Results

      Year 3 Subgroup Analysis (CROI 2021)

      Year 3 Subgroup Analysis (CROI 2021)

      Year 3 Subgroup Analysis (CROI 2021)

    • Suppressed Switch Data

      TANGO Study
      Week 96 Results (Video)

      Week 96 Results (Video)

      Week 96 Results (Video)

      Metabolic Substudy (Video)

      Metabolic Substudy (Video)

      Metabolic Substudy (Video)

      Target Not Detected Results

      Target Not Detected Results

      Target Not Detected Results

      Week 96 Subgroup Analyses

      Week 96 Subgroup Analyses

      Week 96 Subgroup Analyses

    • Real World Evidence

      Summary of Real World Evidence

      Summary of Real World Evidence

      Summary of Real World Evidence